Former FDA Commissioner Joins Bexion Pharmaceuticals Board

COVINGTON, Ky., Jan. 6, 2011 /PRNewswire/ -- Bexion Pharmaceuticals, LLC announced today that it has added Lester Crawford, D.V.M., and Ph.D. to its Board of Directors.

Dr. Crawford has had a distinguished career in the public and private sectors as well as academia. Over ten years of his career were spent at the Food and Drug Administration (FDA) serving in a variety of pivotal roles and culminating in his appointment as FDA Commissioner.

Prior to FDA, Dr. Crawford served in many capacities at the University of Georgia, including chair of the Department of Physiology and Pharmacology and at Georgetown University where he was director of the Center for Food and Nutrition Policy. Dr. Crawford has been an expert advisor to the World Health Organization, the Singapore FDA and the U. S. Academy of Sciences. He is currently a Partner and Senior Science Advisor at Policy Directions, Inc.

"We are excited and privileged to have Dr. Crawford join our Board of Directors," stated Dr. Ray Takigiku, Bexion's co-founder and CEO. "Dr. Crawford brings us important insights on regulatory and industry issues that are vital as we approach an IND submission in 2011, and anticipated clinical trials", added Dr. Takigiku.

"I am especially pleased to join Bexion's Board of Directors," added Dr. Crawford. "I am looking forward to sharing my experience over a long career to help Bexion reach its goal of providing first-in-class, innovative technology to cancer patients worldwide."

About Bexion Pharmaceuticals:

Bexion Pharmaceuticals is focused on the development and commercialization of innovative cures for cancer. Initial products are based on a proprietary platform technology licensed from Cincinnati Children's Hospital Medical Center. The technology has demonstrated potential for development as therapeutic, diagnostic and surgical imaging reagents, and as carriers for other pharmaceutical agents, such as oligonucleotides. For more information, visit www.bexionpharma.com.

SOURCE Bexion Pharmaceuticals